
Edasalonexent
CAS No. 1204317-86-1
Edasalonexent( CAT-1004 | CAT1004 )
Catalog No. M10746 CAS No. 1204317-86-1
Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 267 | Get Quote |
![]() ![]() |
50MG | 1224 | Get Quote |
![]() ![]() |
100MG | 1674 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameEdasalonexent
-
NoteResearch use only, not for human use.
-
Brief DescriptionEdasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).
-
DescriptionEdasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA); significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retriever DMD model; Edasalonexent is hydrolyzed by FAAH to release salicylic acid and DHA intracellularly and to suppress activated NF-κB.Other Indication Phase 2 Clinical.
-
In VitroEdasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and that is designed to synergistically leverage the ability of both of these compounds to inhibit NF-κB. Edasalonexent significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retrieverduchenne muscular dystrophy (DMD) model.
-
In VivoThe treatment of mdx mice with Edasalonexent for 20 weeks results in reduced susceptibility of the extensor digitorum longus muscle to eccentric contraction-induced injury.
-
SynonymsCAT-1004 | CAT1004
-
PathwayApoptosis
-
TargetNF-κB
-
RecptorNF-κB
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number1204317-86-1
-
Formula Weight490.688
-
Molecular FormulaC31H42N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 120 mg/mL (244.56 mM)
-
SMILESO=C(NCCNC(CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)=O)C1=CC=CC=C1O
-
Chemical NameN-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Donovan JM, et al. J Clin Pharmacol. 2017 May;57(5):627-639.
2. Vu CB, et al. J Med Chem. 2016 Feb 11;59(3):1217-31.
molnova catalog



related products
-
A922500
A922500 is an inhibitor for human and mouse DGAT-1 with IC50 of 7 nM and 24 nM, respectively, good selectivity over related acyltransferases, hERG, and a panel of anti-targets.
-
Ergolide
Ergolide inhibits inducible nitric oxide synthase and cyclo-oxygenase-2 expression in RAW 264.7 macrophages through the inactivation of NF-κB.?
-
B022
B022 is a selective and potent NF-κB-induced kinase (NIK) inhibitor (Ki: 4.2 nM) and a chemical probe for treating liver inflammation and injury, protecting the liver from inflammation and injury caused by oxidative stress and toxins.